Skip to content

Study · Animal study (in vivo) · mouse · 1975

2 results

Effects of arecoline and cholinesterase inhibitors on cyclic guanosine 3',5'-monophosphate and adenosine 3'.5'-monophosphate in mouse brain.

Dinnendahl V, Stock K

Naunyn-Schmiedeberg's archives of pharmacology1 Jan 1975Cited by 31 (Europe PMC)

PMID241944 (opens in a new tab)DOI10.1007/bf00510558 (opens in a new tab)PepBankPUB-00241944
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In mice exposed to arecoline, MIF did not affect cGMP values.

    In plain wordsIn mice exposed to arecoline, MIF did not change brain cGMP compared with arecoline stimulation alone.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeBrain cGMP
    Study

    micen: not reported in source

    Arecoline-induced cholinergic stimulation
    Comparator
    Arecoline stimulation without MIF
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The tripeptide prolyl-leucyl-glycinamide (MIF) had no effect on either cGMP values or the peripheral signs of cholinergic stimulation elicited by arecoline.
    1 context sentence
    Summary · context
    In mice, Arecoline in vivo dose-dependently increased the cGMP concentrations of the cerebellum and the "cereberum" (= parts of cortex, hippocampus, hypothalamus, thalamus, striatum and midbrain) without influencing thecAMP levels.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice exposed to arecoline, MIF did not affect peripheral signs of cholinergic stimulation.

    In plain wordsIn mice exposed to arecoline, MIF did not change peripheral cholinergic signs compared with arecoline stimulation alone.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changePeripheral signs of cholinergic stimulation
    Study

    micen: not reported in source

    Arecoline-induced cholinergic stimulation
    Comparator
    Arecoline stimulation without MIF
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The tripeptide prolyl-leucyl-glycinamide (MIF) had no effect on either cGMP values or the peripheral signs of cholinergic stimulation elicited by arecoline.
    1 context sentence
    Summary · context
    In mice, Arecoline in vivo dose-dependently increased the cGMP concentrations of the cerebellum and the "cereberum" (= parts of cortex, hippocampus, hypothalamus, thalamus, striatum and midbrain) without influencing thecAMP levels.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.